Novartis, Bayer Near Deal Over Hemophilia Drugs

Law360, New York (December 10, 2009, 3:43 PM EST) -- The vaccines division of Swiss drugmaker Novartis AG has reached a settlement in principle with Bayer Healthcare LLC in a patent infringement suit over Bayer hemophilia drugs Kogenate and Helixate.

Novartis Vaccines and Diagnostics Inc. and co-plaintiff Novo Nordisk A/S joined defendants Bayer and CSL Behring LLC Wednesday in asking the U.S. District Court for the Eastern District of Texas to stay the case while they work out an agreement.

A Bayer spokeswoman said Thursday that the parties were sufficiently close to settlement to seek a...
To view the full article, register now.